Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ominsky

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 27, 2014
Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibodyMichael S Ominsky, Qing-Tian Niu, Chaoyang Li, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 27, 2007
The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeysM S Ominsky, P J Kostenuik, P Cranmer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 6, 2016
Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus MonkeysDavid C Lee, Aurore Varela, Paul J Kostenuik, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 6, 2014
Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeysPaul J Kostenuik, Susan Y Smith, Rana Samadfam, et al.
Bone|April 5, 2011
Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibodyPaul J Kostenuik, Susan Y Smith, Jacquelin Jolette, et al.
The Journal of Bone and Joint Surgery. American Volume|May 17, 2017
Sclerostin Antibody Treatment Enhances Rotator Cuff Tendon-to-Bone Healing in an Animal ModelShivam A Shah, Ioannis Kormpakis, Necat Havlioglu, et al.
The Journal of Bone and Joint Surgery. American Volume|April 19, 2013
Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat modelMandeep S Virk, Farhang Alaee, Hezhen Tang, et al.
Bone Reports|June 30, 2018
Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized ratsScott Taylor, Rong Hu, Efrain Pacheco, et al.
Bone|April 19, 2011
Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeysMichael S Ominsky, Brian Stouch, Joseph Schroeder, et al.
Bone|September 27, 2015
Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopeniaZahra Achiou, Hechmi Toumi, Jérome Touvier, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 27, 2014
Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibodyMichael S Ominsky, Qing-Tian Niu, Chaoyang Li, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|March 27, 2007
The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeysM S Ominsky, P J Kostenuik, P Cranmer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 6, 2016
Finite Element Analysis of Denosumab Treatment Effects on Vertebral Strength in Ovariectomized Cynomolgus MonkeysDavid C Lee, Aurore Varela, Paul J Kostenuik, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 6, 2014
Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeysPaul J Kostenuik, Susan Y Smith, Rana Samadfam, et al.
Bone|April 5, 2011
Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibodyPaul J Kostenuik, Susan Y Smith, Jacquelin Jolette, et al.
The Journal of Bone and Joint Surgery. American Volume|May 17, 2017
Sclerostin Antibody Treatment Enhances Rotator Cuff Tendon-to-Bone Healing in an Animal ModelShivam A Shah, Ioannis Kormpakis, Necat Havlioglu, et al.
The Journal of Bone and Joint Surgery. American Volume|April 19, 2013
Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat modelMandeep S Virk, Farhang Alaee, Hezhen Tang, et al.
Bone Reports|June 30, 2018
Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized ratsScott Taylor, Rong Hu, Efrain Pacheco, et al.
Bone|April 19, 2011
Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeysMichael S Ominsky, Brian Stouch, Joseph Schroeder, et al.
Bone|September 27, 2015
Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopeniaZahra Achiou, Hechmi Toumi, Jérome Touvier, et al.
Pageof 9